← Oncology Approval Tracker

FDA DECISION ·

Opdivo

nivolumab · Bristol Myers Squibb

FDA approvalNew or expanded indicationUrothelial carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Patients with urothelial carcinoma at high risk of recurrence after radical resection.

LAMPGEN ANALYSIS

Why it matters

The decision introduces adjuvant checkpoint therapy in a high-risk postoperative setting.

What research teams should watch

Record resection date, pathology, recurrence risk and any neoadjuvant therapy before assignment.

PRIMARY RECORDS

Sources